Type:10 Tablets
Generic Name:Saxagliptin
Manufacturer:The Ibn Sina Pharmaceutical Ind. Ltd.
Price:৳200.00
Type 2 diabetes
May be taken with or without food.
Oral Type 2 diabetes mellitus Adult: 2.5 or 5 mg once daily. Combination therapy: May need to reduce dosage of sulfonylurea or other insulin secretagogues when administered in combination Coadministration with strong CYP450 3A4/5 inhibitors: Not to exceed 2.5 mg PO qDay Elderly: No dosage adjustment. Hepatic Impairment No dosage adjustment.
<18 years: Safety and efficacy not established
Renal impairment CrCl >50 mL/min: No dose adjustment required CrCl <50 mL/min: Not to exceed 2.5 mg PO qDay ESRD requiring hemodialysis: Not to exceed 2.5 mg PO qDay administered postdialysis ESRD requiring peritoneal dialysis: Not studied
Documented hypersensitivity (eg, anaphylaxis, angioedema, exfoliative skin conditions)
Dipeptidyl peptidase IV (DPP-4) inhibition that results in increased incretin hormones and enhanced glycemic control.
Renal impairment Decrease dose with strong CYP450 3A4/5 inhibitors Coadministration with thiazolidinediones (eg, rosiglitazone, pioglitazone) increases risk for peripheral edema Pancreatitis reported with saxagliptin; monitor for signs and symptoms and discontinue if pancreatitis suspected Serious hypersensitivity reactions with saxagliptin reported (typically within the first 3 months of therapy) History of angioedema Coadministration with a sulfonylurea or with insulin may increase hypoglycemia; monitor closely and adjust sulfonylurea and/or insulin dose accordingly Congestive heart failure (CHF) risks. Observe patients for signs and symptoms of heart failure during therapy; Lactation: Not known whether distributed in breast milk; caution advised
1-10% (selected) Urinary tract infection (7%),Headache (7%),Hypersensitivity-related events (<4%; eg, urticaria, facial edema),Peripheral edema (<4%; increased incidence when coadministered with thiazolidinediones),Upper respiratory tract infection (3%),Gastroenteritis (2%),Hypoglycemia (1.6%) Frequency Not Defined Increased creatinine phosphokinase,Increased creatinine,Idiopathic thrombocytopenic purpura rash
Strong CYP3A4/5 inhibitors (eg ketoconazole, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir & telithromycin).
